Figure 13.

Estimated weighted mean difference of improvement in central macular thickness (μm) with aflibercept in comparison with ranibizumab at 12 months stratified by randomized controlled trial (RCT) (pictured top) vs. non-RCT (pictured bottom). 12-month RCTs: Weighted mean difference between aflibercept and ranibizumab: –21.55 μm, P = 0.060. 12-month non-RCTs: Weighted mean difference between aflibercept and ranibizumab: –10.12 μm, P = 0.633. Note: Only comparator groups with more than one study in RCT and non-RCT groups were represented in stratified analyses; thus, no comparator groups were represented in stratified analyses at 24 months. Afl: Aflibercept, CI: confidence interval